FDA happenings: More QC troubles at Guidant; Label expansion for Medtronic CRTs; FDA announces Critical Path opportunities list; and more
Around the industry: Boston Scientific-Guidant merger cleared by FTC; Guidant suspends use of Xience V; Conor licenses pimecrolimus from Novartis; and more
Proceedings of TCT 3, 21-24 (2006).
Fluent in Science 